NCT05507970 - First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions

Malaria,Falciparum

Interventions

DRUG

MMV367

Single dose dispersed in sterile water, fasted.

DRUG

Placebo

Single Dose dispersed in sterile water, fasted.

DRUG

MMV367 (Fed 440mg)

Single dose dispersed in sterile water with a high fat meal.

DRUG

MMV367

Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.

DRUG

Placebo

Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.

DRUG

MMV367 (Fasted 440mg)

Single dose dispersed in sterile water fasted.

Trial Locations (1)

Quotient Sciences, Nottingham